Trial Profile
Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Pentostatin
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 09 Feb 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 06 Nov 2009 New trial record